IL298907A - Administering sulcardin for the treatment of acute atrial fibrillation - Google Patents

Administering sulcardin for the treatment of acute atrial fibrillation

Info

Publication number
IL298907A
IL298907A IL298907A IL29890722A IL298907A IL 298907 A IL298907 A IL 298907A IL 298907 A IL298907 A IL 298907A IL 29890722 A IL29890722 A IL 29890722A IL 298907 A IL298907 A IL 298907A
Authority
IL
Israel
Prior art keywords
sulcardine
pharmaceutically acceptable
acceptable salt
administration
tmax
Prior art date
Application number
IL298907A
Other languages
English (en)
Hebrew (he)
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of IL298907A publication Critical patent/IL298907A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298907A 2020-06-12 2021-06-11 Administering sulcardin for the treatment of acute atrial fibrillation IL298907A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
IL298907A true IL298907A (en) 2023-02-01

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298907A IL298907A (en) 2020-06-12 2021-06-11 Administering sulcardin for the treatment of acute atrial fibrillation

Country Status (14)

Country Link
US (2) US11813245B2 (cg-RX-API-DMAC10.html)
EP (1) EP4164633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023529196A (cg-RX-API-DMAC10.html)
KR (1) KR20230024347A (cg-RX-API-DMAC10.html)
CN (1) CN116723836A (cg-RX-API-DMAC10.html)
AU (1) AU2021288056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182015A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003501A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023000194A2 (cg-RX-API-DMAC10.html)
IL (1) IL298907A (cg-RX-API-DMAC10.html)
MX (1) MX2022015834A (cg-RX-API-DMAC10.html)
PH (1) PH12022553396A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021252959A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
WO2026036095A1 (en) * 2024-08-08 2026-02-12 Huyabio International, Llc J-Tp PROTECTION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2020123824A1 (en) * 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Also Published As

Publication number Publication date
US11813245B2 (en) 2023-11-14
US20240058304A1 (en) 2024-02-22
PH12022553396A1 (en) 2024-04-22
EP4164633A4 (en) 2024-07-31
WO2021252959A1 (en) 2021-12-16
JP2023529196A (ja) 2023-07-07
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
BR112022025216A2 (pt) 2023-04-04
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
CN116723836A (zh) 2023-09-08
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09
CO2023000194A2 (es) 2023-03-27
CA3182015A1 (en) 2021-12-16
MX2022015834A (es) 2023-04-04

Similar Documents

Publication Publication Date Title
AU2019397511B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
IL266034B2 (en) Novel polyethylene glycol-modified liposomal apelin formulations for the treatment of cardiovascular diseases
IL279208B1 (en) Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis(benzylsulfanyl)octanoic acid
IL297652B2 (en) Compositions containing methylphenidate prodrugs, processes for their preparation and use
JP6173391B2 (ja) サルカルディン及びその塩の緩速点滴
IL256585A (en) Topical formulations of diacin or raine and their uses
IL312855A (en) ROCK2 inhibitor nanocrystalline preparation and method for its preparation
JP2013511472A5 (cg-RX-API-DMAC10.html)
IL297549A (en) (s)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (apl) for use in the treatment of non-alcoholic steatohepatitis (nash), inflammation of the liver, ballooning of a liver cell, liver fibrosis and fatty liver
JP2012514652A (ja) 心血管疾患および脂質異常症を治療するための分泌ホスホリパーゼａ２（ｓｐｌａ２）インヒビターとナイアシン薬との組成物および方法
KR101059330B1 (ko) 3,７­디아자비시클로〔３,３,１〕노난 화합물을 포함하는 액상의 약제학적 제제 및 부정맥발작에 관련한 치료방법
US20260041665A1 (en) J-Tp Protection
US20100160361A1 (en) Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
KR20050072480A (ko) 투석 환자의 심혈관 사고를 감소시키기 위한 포시노프릴의용도
WO2024086819A2 (en) Diagnosis and treatment of heart failure
IL314334A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2021186001A1 (en) Dose treatments of tauopathies
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
MAN CLINICAL USE OF PROSTACYCLIN IN VASCULAR DISEASE
HK1176858B (en) Slow infusion of sulcardine and its salts